IDYA
Closed
Ideaya Biosciences Inc
21.12
+0.10 (+0.48%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 21.02
Day's Range: 20.5 - 21.94
Send
sign up or login to leave a comment!
When Written:
14.76
Ideaya Biosciences Inc. is a clinical-stage biotechnology company that focuses on developing precision medicine for oncology. The company was founded in 2015 and is headquartered in South San Francisco, California.
Ideaya Biosciences' approach to precision medicine involves identifying and targeting genetic mutations that drive cancer growth. The company uses a proprietary drug discovery platform called Synthetic Lethality, which combines genetic and chemical screens to identify potential drug targets.
Ideaya Biosciences' lead product candidate is IDE196, a small molecule inhibitor that targets a genetic mutation called GNAQ/11, which is found in several types of cancer, including uveal melanoma and other solid tumors. The company is also developing other product candidates that target genetic mutations in cancer cells.
Ideaya Biosciences has collaborations with several pharmaceutical companies, including GlaxoSmithKline, Pfizer, and Novartis. The company has raised over $200 million in funding from investors, including 5AM Ventures, BVF Partners, and Novartis Venture Fund.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Ideaya Biosciences' approach to precision medicine involves identifying and targeting genetic mutations that drive cancer growth. The company uses a proprietary drug discovery platform called Synthetic Lethality, which combines genetic and chemical screens to identify potential drug targets.
Ideaya Biosciences' lead product candidate is IDE196, a small molecule inhibitor that targets a genetic mutation called GNAQ/11, which is found in several types of cancer, including uveal melanoma and other solid tumors. The company is also developing other product candidates that target genetic mutations in cancer cells.
Ideaya Biosciences has collaborations with several pharmaceutical companies, including GlaxoSmithKline, Pfizer, and Novartis. The company has raised over $200 million in funding from investors, including 5AM Ventures, BVF Partners, and Novartis Venture Fund.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!